Paraneoplastic Syndromes: Clinical Trials

44 trials for Paraneoplastic Syndromes, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 recruiting, 12 completed, 7 not yet recruiting, 4 active not recruiting. 44 Phase 1, 12 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 144Recruiting 14, Completed 12, Not yet recruiting 7, Active not recruiting 4, Withdrawn 3, Terminated 2, Unknown 2
Phase 212Recruiting 5, Completed 4, Active not recruiting 2, Not yet recruiting 1

Follow Paraneoplastic Syndromes: new trials by email Literature Review of Paraneoplastic Syndromes trials Research Report on Paraneoplastic Syndromes

Trials (filtered) newest first · largest first

All 44 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
HN2301 injection - Generalized Myasthenia Gravis
Phase 1Not yet recruitingShenzhen MagicRNA Biotechnology Co., Ltd62026-12-312026-08-12
An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis
EA5 - Generalized Myasthenia Gravis (gMG)
Phase 1Not yet recruitingShanghai Lanyi Therapeutics Co., Ltd.182026-09-152026-09-14
Universal STAR-T Cell Injection in Generalized Myasthenia Gravis
Universal STAR-T Cell - Generalized Myasthenia Gravis
Phase 1Not yet recruitingDaishi Tian102026-07-062026-07-20
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
CD20/BCMA-directed CAR-T cells Autologous 2nd generation - Multiple Sclerosis (MS), Myasthenia Gravis (MG)
Phase 1Not yet recruitingThe Affiliated Hospital of Qingdao University182026-07-012026-06-30
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
Aritinercept, Placebo - Myasthenia Gravis, Generalized
Phase 1 / Phase 2RecruitingAurinia Pharmaceuticals Inc.812026-04-222026-08-03
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
KITE-363, Fludarabine, Cyclophosphamide - Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis
Phase 1RecruitingKite, A Gilead Company572026-04-102026-11-17
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase 1RecruitingTongji Hospital62026-04-012026-05-12
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
IM-101 Part A, Placebo Part A, IM-101 Part B - Myasthenia Gravis
Phase 1 / Phase 2RecruitingImmunAbs Inc.962026-02-052026-02-11
Ripertamab for the Treatment of Myasthenia Gravis
ripertamab - Myasthenia Gravis (MG)
Phase 1 / Phase 2Not yet recruitingZhongming Qiu202026-02-012026-01-28
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
Cizutamig - Generalized Myasthenia Gravis
Phase 1RecruitingCandid Therapeutics442025-09-162026-09-02
Oxaloacetate in Myasthenia Gravis
Oxaloacetate, Placebo - Myasthenia Gravis
Phase 1WithdrawnUniversity of Kansas Medical Center2025-08-012025-07-11
A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
LCAR-AIO T cells - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disease (NMOSD)
Phase 1WithdrawnUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology2025-06-172026-06-24
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
Azercabtagene zapreleucel (azer-cel) - B-cell Mediated Autoimmune Disorders
Phase 1RecruitingTG Therapeutics, Inc.1002025-05-062026-10-27
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
universal allogeneic anti-CD19/BCMA CAR T-cells - Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia
Phase 1Not yet recruitingChangzhou No.2 People's Hospital182025-05-012025-05-18
The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis
Dose level 1 group, Dose level 2 group, Dose level 3 group - Myasthenia Gravis, Generalized
Phase 1Active not recruitingTing Chang, MD102025-05-012026-05-27
Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases
anito-cel, Cyclophosphamide, Fludarabine - Muscular Diseases, Neuromuscular Manifestations
Phase 1RecruitingKite, A Gilead Company302025-04-302026-10-22
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
YTB323 - Generalized Myasthenia Gravis
Phase 1 / Phase 2Active not recruitingNovartis Pharmaceuticals152025-04-222026-09-04
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
BAFF-R CART - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, NMO Spectrum Disorder
Phase 1 / Phase 2RecruitingTianjin Medical University General Hospital272025-04-102026-10-16
A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis
SYS6020 injection - Myasthenia Gravis
Phase 1RecruitingCSPC ZhongQi Pharmaceutical Technology Co., Ltd.602025-03-042026-08-12
An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis
GC012F injection - Generalized Myasthenia Gravis (gMG)
Phase 1Not yet recruitingChongbo Zhao182025-02-152025-01-06

Showing 20 of 44. Sign in to see all of them.

Narrower conditions

Myasthenia Gravis (34)  ·  Multiple Sclerosis (9)  ·  Neuromyelitis Optica (9)  ·  Lupus Erythematosus, Systemic (4)  ·  Myelitis, Transverse (4)  ·  Myositis (4)  ·  Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (4)  ·  Scleroderma, Systemic (4)  ·  Autoimmune Diseases (3)  ·  Zollinger-Ellison Syndrome (3)  ·  ACTH Syndrome, Ectopic (2)  ·  Adrenal Cortex Neoplasms (2)  ·  Autoimmune Diseases of the Nervous System (2)  ·  Carcinoma, Medullary (2)  ·  Carcinoma, Merkel Cell (2)

Broader conditions

Neoplasms (44)  ·  Neoplasms by Site (42)  ·  Nervous System Diseases (40)  ·  Nervous System Neoplasms (39)  ·  Neurodegenerative Diseases (39)  ·  Paraneoplastic Syndromes, Nervous System (39)  ·  Immune System Diseases (37)  ·  Autoimmune Diseases of the Nervous System (36)  ·  Autoimmune Diseases (35)  ·  Neuromuscular Junction Diseases (34)  ·  Neuromuscular Diseases (33)  ·  Demyelinating Autoimmune Diseases, CNS (13)  ·  Demyelinating Diseases (13)  ·  Cranial Nerve Diseases (10)

Interventions

Cyclophosphamide (5)  ·  fludarabine (4)  ·  Rituximab (3)  ·  Acetates (1)  ·  Capecitabine (1)  ·  Clopidogrel (1)  ·  Dexlansoprazole (1)  ·  Esomeprazole (1)  ·  Everolimus (1)  ·  Exercise (1)  ·  Granulocyte Colony-Stimulating Factor (1)  ·  Hematopoietic Stem Cell Transplantation (1)  ·  Hizentra (1)  ·  LFB-R603 (1)  ·  Lansoprazole (1)

Sponsors

Cabaletta Bio (2)  ·  Kite, A Gilead Company (2)  ·  Ting Chang, MD (2)  ·  Abide Therapeutics (1)  ·  Aurinia Pharmaceuticals Inc. (1)  ·  Baltimore VA Medical Center (1)  ·  COUR Pharmaceutical Development Company, Inc. (1)  ·  CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1)  ·  Candid Therapeutics (1)  ·  Changzhou No.2 People's Hospital (1)  ·  Chongbo Zhao (1)  ·  Corcept Therapeutics (1)  ·  Crinetics Pharmaceuticals Inc. (1)  ·  CuraVac (1)  ·  Daishi Tian (1)

Countries

United States (23)  ·  China (16)  ·  United Kingdom (3)  ·  Belgium (2)  ·  France (2)  ·  Spain (2)  ·  Australia (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  Germany (1)  ·  Israel (1)  ·  Italy (1)  ·  Japan (1)  ·  Poland (1)  ·  Serbia (1)

Top investigators

Daishi Tian (2)  ·  Andreas G Moraitis, MD (1)  ·  Anu Jacob, MD DM FRCP (1)  ·  Benjamin Greenberg, MD (1)  ·  Bruce Cree, MD, PhD (1)  ·  Charlene E Hafer-Macko, MD (1)  ·  Chuan Qin (1)  ·  Ghazala Hayat, M.D. (1)  ·  He Huang, MD (1)  ·  Jacqueline Palace, FRCP DM (1)  ·  Jafar Kafaie, M.D. (1)  ·  James Yao (1)

Results publications

PMID 19838774, PMID 20606544, PMID 21211990, PMID 22464259, PMID 23333143, PMID 25900182, PMID 39720510, PMID 41747738

NIH funding

2015 (1), 2023 (1), 2025 (1), P30CA016672 (1), U01CA062461 (1)